New targeted therapy shows promise for Tough-to-Treat lymphomas
NCT ID NCT05453396
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a drug called loncastuximab tesirine in adults with B-cell lymphomas that have returned or not responded to prior treatment. The drug works like a smart bomb, attaching to a marker on cancer cells and delivering chemotherapy directly to them. The main goal is to see how many patients' tumors shrink or disappear. About 20 people will take part.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, 98109, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Multi-Drug combo outsmart resistant lymphoma?
- Can a new drug combo shield young hearts from transplant complications?
- Could adjusting chemo doses boost CAR T-Cell success against tough lymphoma?
- Radiation boost may supercharge CAR T-Cell therapy against tough lymphoma
- Combination therapy aims to outsmart tough lymphoma
- Targeted drug combo aims to tackle Hard-to-Treat lymphoma